Novo Nordisk (NVO) stock is in focus as the company plans to launch Ozempic pill for children with type 2 diabetes after a ...
Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results